GSK’s Nucala receives US FDA approval for use in adults with chronic obstructive pulmonary disease: London, UK Saturday, May 24, 2025, 11:00 Hrs [IST] GSK plc announced that the ...

GSK stock dips 0.6% after six-session gain streak. EU panel backs Blenrep for multiple myeloma, while FDA expands asthma ...

Who doesn’t love a comeback story? Certainly not GSK, which has found a way to resuscitate its cancer treatment Blenrep as a ...

CHMP gives positive opinions for new drugs from GSK, Roche & SpringWorks, including GSK's Blenrep, Roche's Itovebi & ...

The U.S. Food and Drug Administration has approved British drugmaker GSK's asthma drug to treat some patients with a chronic ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud.

The FDA has approved Nucala (mepolizumab) as an add-on maintenance treatment for certain COPD patients whose disease isn't ...

The FDA has granted approval to GSK's Nucala as an add-on maintenance treatment for adult patients suffering from inadequately controlled COPD.

The approval tees GSK up to challenge Sanofi and Regeneron, which in September 2024 won the first biologic approval for COPD ...

GSK (GSK) stock in focus as its antibody drug conjugate Blenrep gains EMA recommendation for relapsed multiple myeloma with ...

Nucula’s new indication is as an add-on therapy for patients with COPD who also have an elevated blood eosinophil count.

The recommendation by the Committee for Medicinal Products for Human Use--also known as CHMP--follows the approval of Blenrep combinations by the U.K.'s Medicines and Healthcare products Regulatory ...